US Congress Committee Issues Report On “Highly Invasive” FDA Surveillance Of Employees 26/02/2014 by Intellectual Property Watch Leave a Comment The United States House of Representatives Committee on Oversight and Government Reform today released a report detailing the US Food and Drug Administration’s “highly-invasive” surveillance programme that monitored employees who contacted Congress and the media, according to a press release from the committee leaders. Surveillance was unauthorised and whistleblowers were not given sufficient protection, the report found.
Infojustice: Graphics Show Rise In US Pharma Exports To India, Patent Grants By India 24/02/2014 by Intellectual Property Watch Leave a Comment Mike Palmedo at Infojustice.org writes: “The U.S. International Trade Commission (ITC) is currently investigating “Indian industrial policies that discriminate against U.S. imports… and the effect those barriers have on the U.S. economy and U.S. jobs.” The investigation was requested by Sen. Hatch, Sen. Baucus, Rep. Camp, and Rep. Levin, and the final report is due to be released in November. Last week it held a series of hearings, where it heard from U.S. business, Indian business, and civil society representatives.”
Infojustice.org: Australia Commits To Overhaul Of Copyright Act 18/02/2014 by Intellectual Property Watch Leave a Comment From infojustice.org: [Australian Digital Alliance] It has been a big week for Australian Copyright. On Thursday the Attorney-General, the Hon George Brandis QC, tabled the long-anticipated final report from the Australian Law Reform Commission’s (ALRC) Copyright and the Digital Economy inquiry. This inquiry was charged with determining if copyright exceptions and limitations were working in the digital age. The conclusion was that reform was needed.
South Africa Promotion And Protection Of Investment Bill 2013 – A Review 13/02/2014 by Intellectual Property Watch 2 Comments On 1 November 2013, the South African Department of Trade and Industry published the draft “Promotion and Protection of Investment Bill” for comments. And two lawyers caution that if not careful, it could come in conflict with the country’s international intellectual property obligations.
Alert: Pharma IPR 2014 Conference In Mumbai, 26-28 February 10/02/2014 by Intellectual Property Watch Leave a Comment Dear Subscribers, CPhI’s 3rd Annual Pharma IPR 2014 conference to take place from 26-28 February, 2014 in Mumbai, India will have techno-legal experts from over 10+ regions speaking on the recent case studies on global Pharma and Biopharma patent laws. Among them, Jeffery Alan Hovden, Partner, Robins, Kaplan, Miller & Ciresi LLP from US will be speaking on critical developments in US pharma patent law in the year 2013 which have affected pharma and biopharma industry. He will also share best strategies on how Indian generic-drug and biologics enterprises need to go forward with their US-related projects. Some of the critical concerns he is planning to address include: Which pharmaceutical and diagnostic compounds and processes can even obtain a US patent? Whether the new, cheap and fast patent-challenge procedures are right for Indian companies in the life-sciences area? How to avoid paying the attorney fees for the other side in US litigation and indeed, how an Indian company might turn the tables and have the other side pay the company’s attorney fees? You can view his insights on “US Patent Law in 2013: Winds of Change” by clicking here. To optimise interactions with the audience, he and other global techno-legal experts would also be available in query handling sessions as well as one-on-one meetings, to discuss your concerns related to the US patent system. Click here to go through the detailed programme agenda. You can read more about the conference speakers here. To be a part of this exclusive event, please contact the organisers at +91 (22) 6172 7001 / conferences-india@ubm.com, or register online and take advantage of the special offers for you as you are our subscribers. P.S. You may find one of his earlier presentations on “From Small to Big: Some useful points in the coming shift from customary drugs to biologics” interesting – View the presentation here
Global Health 2035 Report: Flawed Projections 23/01/2014 by Intellectual Property Watch 3 Comments Daniele Dionisio writes: Hopes that a comprehensive global health goal could be reached by 2035 are hardly credible with the load of unresolved issues still on the table. This article turns the spotlight on much-debated relevant questions that were left out or under-scrutinised in a recently published Lancet report.
New QUNO Reports Encourage Plant Variety Protection Alternatives 17/01/2014 by Intellectual Property Watch Leave a Comment The Quaker UN Office in Geneva has announced two new publications on intellectual property, agriculture, food and biological diversity.
Event: The 6th Annual Corporate IP Counsel Forum 13/01/2014 by Intellectual Property Watch Leave a Comment March 19-20, 2014 – Affinia Manhattan – New York City – www.worldcongress.com/corporateIP Optimize your IP portfolio. In this cross-industry event, the most timely and critical issues will be discussed and analyzed by senior counsel from Bank of America, General Mills, Honeywell, IBM, MLB Advanced Media, MasterCard, S.C. Johnson, and more; providing insight and strategies to help you tackle the latest challenges in IP. IP-Watch Reader Discount: when reserving your seat, use promo code IPW200 to take $200.00 off the current registration fee.
New EU Customs Enforcement Regulation On IPRs Takes Effect 09/01/2014 by Intellectual Property Watch Leave a Comment A new regulation on the enforcement of intellectual property rights took effect in the European Union on 1 January, strengthening enforcement and extending the range of rights protected, according to a legal analysis.
New Research Handbook On IP Licensing Available 08/01/2014 by Intellectual Property Watch Leave a Comment A recently released book titled, “The Research Handbook on Intellectual Property Licensing,” explores the complexities of intellectual property licensing law from a comparative perspective through the opinions of leading experts.